Abstract:Abstract Background: The clinical and molecular factors that associated with the response to Osimertinib in the patients who have acquired resistance to the first or second-generation of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) is elusive.Objectives: The purpose of this study is to investigate the clinical relevance to the allele frequency (AF) of T790M in circulating tumor DNA (ctDNA) by targeted next generation sequencing (NGS), and to analyze the prognostic value of T790M AF in patients with advanced non-small cell lung cancer (NSCLC) receiving Osimertinib after resistance to the first-or second-generation of EGFR-TKIs.Materials and methods: We retrospectively screened 3011 advanced NSCLC patients in the First Affiliated Hospital of Xi’an Jiaotong University from November 2015 to March 2021. 586 of them experienced the first- or second-generation EGFR-TKIs resistance and had complete follow-up information, 146 of them took NGS gene test and 48 were detected EGFR T790M in ctDNA. The associations among T790M AF, clinical characteristics and objective response rate (ORR) of Osimertinib was performed by Students’ t-test or one-way ANOVA. The patients were divided into T790M-high and T790M-low groups according to a receiver operation curve (ROC) determined cut-off value. The correlation between T790M AF and ORR of Osimertinib was performed by Students’ t-test, and the association between clinical factors and ORR of Osimertinib was assessed by Pearson’s χ2 test or Fisher’s exact test, when appropriate. The survival curves were calculated by the Kaplan-Meier method and analyzed by the log-rank test. Cox proportional hazards regression models were also used to evaluate the association between clinical characteristics, T790M AF and survival endpoints.Results: Age (P=0.004), EGFR active mutations (P<0.001), EGFR T790M AF (P=0.014), prior EGFR-TKIs (P=0.024) and liver metastasis before Osimertinib treatment (P=0.031) were significantly associated with progression-free survival (PFS). Multivariate analysis revealed that age (hazard ratio: 0.32, 95%CI: 0.13-0.75, P=0.009) and the AF of EGFR T790M (hazard ratio: 0.39, 95%CI: 0.17-0.90, P=0.027) were independent prognostic factors for PFS in EGFR T790M positive advanced NSCLC patients receiving Osimertinib. EGFR active mutations (P<0.001) was significantly associated with overall survival (OS). EGFR T790M AF tended to be related to OS (P=0.066). Moreover, high EGFR T790M AF (HR: 0.31, 95%CI: 0.10-0.92, P=0.035) and EGFR active mutations (HR: 2.28, 95%CI: 1.07-4.90, P=0.015) were independently predictive factors of OS in multivariate analysis.Conclusion: EGFR T790M AF in ctDNA independently predicted PFS and OS in T790M-positive advanced NSCLC who received Osimertinib after resistance to the first- or second-generation of EGFR-TKIs.

MA15.10 Loss of T790M Mutation is Associated with Early Progression to Osimertinib in Chinese Advanced NSCLC Patients Harboring EGFR T790M

Loss of T790M Mutation is Associated with Early Progression to Osimertinib in Chinese Patients with Advanced NSCLC Who Are Harboring EGFR T790M.

T790M Mutation is Associated with Better Efficacy of Treatment Beyond Progression with EGFR-TKI in Advanced NSCLC Patients.

Clinical Factors Affecting the Response to Osimertinib in Non-Small Cell Lung Cancer Patients with an Acquired Epidermal Growth Factor Receptor T790M Mutation: A Long-Term Survival Analysis

Primary and Acquired EGFR T790M-mutant NSCLC Patients Identified by Routine Mutation Testing Show Different Characteristics but May Both Respond to Osimertinib Treatment

The Impact of EGFR T790M Mutation Status Following the Development of Osimertinib Resistance on the Efficacy of Osimertinib in Non‐small Cell Lung Cancer: A Meta‐analysis

Risk Factors of Acquired T790M Mutation in Patients with Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer

A Comprehensive Prognostic Analysis of Osimertinib Treatment in Advanced Non-Small Cell Lung Cancer Patients with Acquired EGFR-T790M Mutation: a Real-World Study

1369P EGFR T790M Ctdna Abundance and TP53 Co-Mutation by Next Generation Sequencing Predicted Clinical Outcomes of Osimertinib in Non-Small Cell Lung Cancer Patients from a Real-World Study

The Status of the EGFR T790M Mutation is Associated with the Clinical Benefits of Osimertinib Treatment in Non-small Cell Lung Cancer Patients: A Meta-Analysis

<i>EGFR</i> mutation genotypes affect efficacy and resistance mechanisms of osimertinib in T790M-positive NSCLC patients

Different Characteristics and Survival in Non‐small Cell Lung Cancer Patients with Primary and Acquired EGFR T790M Mutation

Survival benefit of osimertinib combination therapy in patients with T790M-positive non-small-cell lung cancer refractory to osimertinib treatment

Low T790m Relative Allele Frequency Indicates Concurrent Resistance Mechanisms And Poor Responsiveness To Osimertinib

Novel Mutations on EGFR Leu792 Potentially Correlate to Acquired Resistance to Osimertinib in Advanced NSCLC.

Comprehensive analysis of EGFR T790M detection by ddPCR and ARMS-PCR and the effect of mutant abundance on the efficacy of osimertinib in NSCLC patients

Significant Benefits of Osimertinib in Treating Acquired Resistance to First-Generation EGFR-TKIs in Lung Squamous Cell Cancer: A Case Report.

Monitoring of Plasma EGFR Mutations during Osimertinib Treatment for NSCLC Patients with Acquired T790M Mutation

Insensitivity to T790M Mutation? A Pooled Analysis of Outcomes Following Osimertinib for the Treatment of NSCLC Patients Harboring Uncommon Epidermal Growth Factor Receptor Mutation

Differential prognostic value of tumor and plasma T790M mutations in EGFR TKI-treated advanced NSCLC

The allele frequency of EGFR T790M in ctDNA predicted clinical outcomes of Osimertinib in non-small cell lung cancer patients from a real-world study